Rheumatology · Oakland, CA
NPI
1992934632
Since 2009
Specialty
Rheumatology
Code 390200000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3701 Broadway, 3rd Floor
Oakland, CA, 94611
Phone (510) 752-1275
Groups this clinician bills Medicare through
Medicare paid, 2022
$10K
353 services
Medicare patients, 2022
13
Average age 60
Drug cost, 2024
$2.0M
2,269 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Pei-Chang P Chen prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 580 prescriptions and refills. In total Pei-Chang P Chen wrote 2,269 Medicare prescriptions that cost $2.0M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-10.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Methotrexate Methotrexate Sodium | 580 | 1,603 | 174 | $12K |
| Hydroxychloroquine Sulfate Generic | 354 | 1,142 | 127 | $12K |
| Prednisone Generic | 270 | 670 | 101 | $3,332 |
| Enbrel Sureclick Etanercept | 100 | 105 | 14 | $488K |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 81 | 156 | 19 | $150K |
| Enbrel Etanercept | 58 | 58 | Under 11 | $283K |
| Sulfasalazine Generic | 51 | 151 | 17 | $3,726 |
| Leflunomide Generic | 50 | 163 | 19 | $1,521 |
| Otezla Apremilast | 42 | 42 | Under 11 | $166K |
| Colchicine Generic | 41 | 106 | 20 | $1,409 |
| Famotidine Generic | 40 | 130 | 15 | $504 |
| Mycophenolate Mofetil Generic | 34 | 110 | 11 | $4,645 |
| Xeljanz Tofacitinib Citrate | 30 | 38 | Under 11 | $93K |
| Amjevita(Cf) Adalimumab-Atto | 30 | 72 | Under 11 | $68K |
| Cevimeline Hcl Generic | 29 | 74 | Under 11 | $6,540 |
Brand drugs: 624 claims; generic drugs: 1,616 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Pei-Chang P Chen were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.